Dhenne Avocats in the press
Specialist and general-interest media report on Dhenne Avocats’ practice, cases and analysis of patent law and innovation.
Specialist press
French firms respond to the UPC
JUVE mentions Dhenne Avocats among the boutiques active before the UPC and reports on its national litigation practice.
Fischerwerke and the dispute with Art Color
A report on patent litigation conducted by Dhenne Avocats for Fischerwerke.
Early litigation before the UPC
In its article on Fives and Reel, JUVE separately mentions Matthieu Dhenne as part of the team acting for Canè.
Salveco: patents, evidence and trade secrets
JUVE reports on Dhenne Avocats’ work in plant-based chemistry litigation.
Patent litigation in France
An interview on France as a jurisdiction for patent owners.
Why France could not manufacture vaccines
An interview with Aurélie Elbaz.
The firm’s cases in the press
eBikeLabs and Cowboy: a dispute over electric-bike technology
Media outlets reported on this case in which Dhenne Avocats represents eBikeLabs. The references below were brought together in the firm’s archive of coverage of the dispute.
General-interest media
Interviews and quotations
Vaccines and the proposed patent waiver
A joint interview with economist Nathalie Coutinet.
Vaccine nationalism and access to vaccines
Matthieu Dhenne is quoted in an analysis of possible responses to the pandemic.
Radio and television
Les visiteurs du soir
A discussion of the role of patents in research.
Why Moderna sued Pfizer
La Question du jour, with Guillaume Erner.
Debate on waiving vaccine patents
Votre instant politique: a debate with Manon Aubry.
What would a vaccine patent waiver change?
An interview on patents and access to Covid-19 vaccines.
Patents and access to vaccines in Africa
A contribution to a report on access to vaccines.
Intellectual property and the pandemic response
Éco d’ici, éco d’ailleurs: a discussion with Pierre-Yves Geoffard, Carine Milcent and Fabienne Orsi.
Should vaccine patents become global public goods?
The firm’s archive of this interview about Covid-19 vaccines.
Articles and appearances identified in the archives as of 13 October 2026. Links lead to the media outlet or, where a direct programme link was not found, to the firm’s archive. Historical references are dated.